EDAP Reports Interim Data from P-III Trial of Robotic HIFU for Treating Deep Infiltrating Endometriosis
Shots:
- The P-III trial assesses acute pelvic pain levels after robotic High-Intensity Focused Ultrasound (HIFU) therapy or sham treatment among deep infiltrating endometriosis patients (n=60), followed for 3mos.
- The 1EP of decrease in acute pelvic pain was not reached, although significant reduction in pelvic pain scores, evaluated by Visual Analog Scale (VAS), after 3mos. was observed across both arms; MRI measurements showed greater reductions in endometriosis nodule volume with HIFU vs Sham treatment
- Safety profile was favorable, verifying the results of P-I & P-II trials. The trial continues, with Sham treatment patients opting for HIFU therapy after their pelvic pain returned to baseline; further updates are anticipated later in 2024
Ref: EDAP | Image: EDAP
Related news:- Bionomics Reports the Commencement of P-III (AFFIRM-1) Study Evaluating BNC210 for Social Anxiety Disorder (SAD)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
